Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease

Parkinsonism and Related Disorders

Volumn 21, Issue 5, 2015, Pages 514-520

  Zesiewicz, Theresa A ^a   Evatt, Marian ^b   Vaughan, Camille P ^b   Jahan, Israt ^a   Singer, Carlos ^c   Ordorica, Raul ^a   Salemi, Jason L ^d   Shaw, Jessica D ^a   Sullivan, Kelly L ^e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

^e GEORGIA SOUTHERN UNIVERSITY   (United States)

Author keywords

Non motor symptoms; Overactive bladder; Parkinson's disease; Solifenacin succinate; Urinary incontinence

Indexed keywords

PLACEBO; SOLIFENACIN; URINARY TRACT AGENT;

AGED; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; MALE; MICTURITION; MULTICENTER STUDY; NOCTURIA; OVERACTIVE BLADDER; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; URINE INCONTINENCE; URINE RETENTION; XEROSTOMIA; CLINICAL TRIAL; PILOT STUDY; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PILOT PROJECTS; SOLIFENACIN SUCCINATE; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE; UROLOGICAL AGENTS;

EID: 84928588814     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2015.02.025     Document Type: Article

References (23)

1. Pohar S.L., Allyson Jones C. The burden of Parkinson disease (PD) and concomitant comorbidities. Arch Gerontol Geriatr 2009, 49:317-321.
2. Gallagher D.A., Lees A.J., Schrag A. What are the most important nonmotor symptoms in patients with Parkinson's disease and are we missing them?. Mov Disord 2010, 25:2493-2500.
3. Araki I., Kuno S. Assessment of voiding dysfunction in Parkinson's disease by the international prostate symptom score. JNeurol Neurosurg Psychiatry 2000, 68:429-433.
4. Campos-Sousa R.N., Quagliato E., da Silva B.B., de Carvalho R.M., Ribeiro S.C., de Carvalho D.F. Urinary symptoms in Parkinson's disease: prevalence and associated factors. Arq Neuropsiquiatr 2003 Jun, 61:359-363.
5. Lemack G.E., Dewey R.B. Questionnaire-based assessment of bladder dysfunction in patients with mild to moderate Parkinson's disease. Urology 2000, 56:250-254.
6. Winge K., Fowler C.J. Bladder dysfunction in Parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006, 21:737-745.
7. Andersson K.E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 2011, 59:377-386.
8. Wagg A., Gibson W., Ostaszkiewicz J., Johnson T., Markland A., Palmer M.H., et al. Urinary incontinence in frail elderly persons: report from the 5th international consultation on incontinence. Neurourol Urodyn 2014, 10.1002/nau.22602.
9. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease. A clinico-pathological study of 100 cases. JNeurol Neurosurg Psychiatry 1992, 55:181-184.
10. Cartwright R., Panayi D., Cardozo L., Khullar V. Reliability and normal ranges for the patient's perception of intensity of urgency scale in asymptomatic women. BJU Int 2010, 105:832-836.
11. Coyne K.S., Matza L.S., Kopp Z., Abrams P. The validation of the patient perception of bladder condition (PPBC): a single-item global measure for patients with overactive bladder. Eur Urol 2006 Jun, 49:1079-1086.
12. de Boer A.G., Wijker W., Speelman J.D., de Haes J.C. Quality of life in patients with Parkinson's disease: development of a questionnaire. JNeurol Neurosurg Psychiatry 1996, 61:70-74.
13. Patrick D.L., Martin M.L., Bushnell D.M., Yalcin I., Wagner T.H., Buesching D.P. Quality of life of women with urinary incontinence: further development of the incontinence quality of life instrument (I-QOL). Urology 1999, 53:71-76.
14. Fahn S., Elton R.L. UPDRS program members. Unified Parkinsons disease rating scale. Recent developments in Parkinsons disease 1987, vol. 2:153-163. Macmillan Healthcare Information, Florham Park, NJ.
15. Morris S.B., DeShon R.P. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods 2002, 7:105-125.
16. Becker B.J. Synthesizing standardized mean change measures. Br J Math Stat Psychol 1988, 41:257-278.
17. Kadel R.P., Kip K.E. ASAS macro to compute effect size (Cohen's d) and its confidence interval from raw survey data. Proceedings of the Annual Southeast SAS Users Group Conference 2012, paper SD-06.
18. K1 Winge, Skau A.M., Stimpel H., Nielsen K.K., Werdelin L. Prevalence of bladder dysfunction in Parkinson disease. Neurourol Urodyn 2006, 25:116-122.
19. Zesiewicz T.A., Sullivan K.L., Arnulf I., Chaudhuri K.R., Morgan J.C., Gronseth G.S., et al. Standards Subcommittee of the American Academy of Neurology. Practice parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010, 74:924-931.
20. Chapple C.R., Khullar V., Gabriel Z., Muston D., Bitoun C.E., Weinstein D. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008, 54:543-562.
21. Jost W.H. Urological problems in Parkinson's disease: clinical aspects. JNeural Transm 2013, 120(4):587-591.
22. Wagg A., Dale M., Tretter R., Stow B., Compion G. Randomised, multicentre, placebo-controlled, double-blind crossover study investigating the effect of solifenacin and oxybutynin in elderly people with mild cognitive impairment: the SENIOR study. Eur Urol 2013, 64:74-81.
23. Araki I., Kitahara M., Oida T., Kuno S. Voiding dysfunction and Parkinson's disease: urodynamic abnormalities and urinary symptoms. JUrol 2000, 164:1640-1643.